Latest Press Release on drugs

HHS Orders Intravenous Antiviral Flu Medication to Help Patients Hospitalized with 2009 H1N1
WASHINGTON - The U.S. Department of Health and Human Services (HHS) today announced contract awards for up to 120,000 treatment courses of intravenous (IV) antiviral drugs to help treat hospitalized 2009 H1N1 influenza patients. Patients hospitalized with 2009 H1N1 influenza

---

AllTranz Awarded $4 Million Research Grant by NIH and NIDA
LEXINGTON, Ky. - AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of t

---

Reportlinker Adds Chinese Markets for Respiratory Drugs
NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Chinese Markets for Respiratory Drugs ...

---

Reportlinker Adds Chinese Markets for Brain Cancer Treatment Drugs
NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Chinese Markets for Brain Cancer Treatment Drugs

---

Viriathus Research Issues an Update Report for Viralytics Limited
NEW YORK - Viriathus Research LLC, an independent research firm, issued an Update Report today for Viralytics Limited (ASX: VLA) (OTC: VRACY), a biotechnology company that is developing therapies and drugs for the treatment of cancer in Australia. The report provides a

---

NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer® NOX-A12
BERLIN - NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer

---

Maxygen Reports Third Quarter 2009 Financial Results
REDWOOD CITY, Calif. - Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced financial results for the quarter ended September 30, 2009. Third Quarter 2009 Financial Results

---

NPDrugs.com Posts Reliable User Feedbacks on Online Pharmacies
(EMAILWIRE.COM, November 06, 2009 ) Ca, USA - NPDrugs.com features user reviewed pharmacies to help internet users who want to buy prescription drugs from a reliable online pharmacy. NPDrugs.com updates its website regularly based on customer input. ..

---

Reportlinker Adds Chinese Markets for Anti-Tumor Drugs
NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Chinese Markets for Anti-Tumor Drugs

---

Neurogen Corporation Announces Third Quarter 2009 Financial Results and Updates Operations
BRANFORD, Conn. - Neurogen Corporation (NASDAQ: NRGN), a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009. The Company also announced its analysis

---

California American Water Celebrates 'No Drugs Down The Drain' Week in Ventura
NEWBURY PARK, Calif., Nov. 6 /PRNewswire/ -- California American Water has designated the week of November 9, 2009 as "No Drugs Down the Drain" week for its Ventura County service area as part of a national campaign sponsored by public and private agencies alike toward...

---

California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego
SAN DIEGO, Nov. 6 /PRNewswire/ -- California American Water has designated the week of November 9, 2009 as "No Drugs Down the Drain" week for its San Diego County service area as part of a national campaign sponsored by public and private agencies alike toward the comm...

---

California American Water Celebrates 'No Drugs Down the Drain' Week in Sacramento
SACRAMENTO, Calif., Nov. 6 /PRNewswire/ -- California American Water has designated the week of November 9, 2009 as "No Drugs Down the Drain" week for its Sacramento service area as part of a national campaign sponsored by public and private agencies alike toward the c...

---

California American Water Celebrates 'No Drugs Down the Drain' Week in Los Angeles
LOS ANGELES, Nov. 6 /PRNewswire/ -- California American Water has designated the week of November 9, 2009 as "No Drugs Down the Drain" Week for its Los Angeles service area as part of a national campaign sponsored by public and private agencies alike toward the common ...

---

AVI BioPharma Announces Third Quarter 2009 Financial Results Conference Call
BOTHELL, WA -- 11/02/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will hold a conference call to report third quarter 2009 financial results on Monday, Nov. 9, 2009, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time).

---

Study Finds Lack of Diffusible VEGF Growth Factor Can Cause Retinal Defects Similar to Dry Macular Degeneration
Discovery may also have impact on the use of new drugs for wet macular degeneration BOSTON, Nov. 2 /PRNewswire-USNewswire/ -- Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth f...

---

Avila Presents Data on Its Novel, Orally-Available Protease Inhibitor, AVL-181, Demonstrating Viral Clearance of Hepatitis C Virus in Preclinical Models
BOSTON & WALTHAM, Mass. - Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, A

---

Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
CAMBRIDGE, Mass., Nov. 3 -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today that it has initiated a Phase II clinical trial evaluating...

---

Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform
CLARKSVILLE, Md., Nov. 4 /PRNewswire/ -- Neuronascent, Inc., a privately-held biotechnology company developing novel, neurogenic small-molecule drugs for the treatment of depression, Alzheimer's disease, Parkinson's and other neurodegenerative diseases, announces it has entered into a disco...

---

Statins May Worsen Symptoms in Some Cardiac Patients
SAN DIEGO, Nov. 4 /PRNewswire-USNewswire/ -- Although statins are widely used to prevent heart attacks, strokes, and other cardiovascular disorders, new research shows that the class of drugs may actually have negative effects on some cardiac patients. A new study presented at CHEST 2009, t...

---

Study Finds Life-Threatening Risks from Medication Errors in Hospitals Treating Pulmonary Hypertension Patients
SAN DIEGO, Nov. 4 -- Pulmonary arterial hypertension (PAH) patients using infused drugs have suffered serious injury or in some cases died from medication errors in hospitals and other inpatient settings, according to a peer-reviewed study by Accredo Health Group ...

---

Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results
LEXINGTON, Mass. - Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended September 30, 2009.

---

Lotus Pharmaceuticals, Inc. Announces Certain Clarification to its Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report for the Quarter ended June 30, 2009
BEIJING, Nov. 5 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical pro...

---